

ATTORNEY'S DOCKET NO. C1039/7049 (HCL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No: Not Assigned
Filed: April 2, 2001 – Filed Herewith
For: METHODS AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM
USING IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINES
Examiner: Not Assigned
Art Unit: Not Assigned

#4/K.T.
4/8
PRG
A

Box Patent Application
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

In the Specification:

Please insert the following paragraph on page 1, in the first line after the title as follows:

This application is a divisional of U.S. Patent Application Serial Number 09/286,098, filed April 2, 1999, ^{U.S.N. 6,218,371} pending, which claims priority under 35 U.S.C. §119(e) from U.S. Provisional Application Serial Number 60/080,729 (now abandoned) filed April 3, 1998. The entire contents of all the foregoing patent applications are incorporated by reference herein.

Please re-write the paragraph starting on page 16, line 13, as follows:

As described in co-pending patent application US Serial No. 08/960,774, oligonucleotides containing an unmethylated CpG motif (i.e. TCCATGACGTTCTGACGTT; SEQ IN NO: 100), but not a control oligonucleotide (TCCATGAGCTTCCTGAGTCT; SEQ ID NO: 103) prevented the development of an inflammatory cellular infiltrate and eosinophilia in a murine model of asthma. Furthermore, the suppression of eosinophilic inflammation was associated with a suppression of Th2 response and induction of a Th1 response.

Please re-write the paragraph starting on page 33, line 26, as follows:

The nucleic acid sequences of the invention which are useful for inducing immune remodeling are those broadly described above and disclosed in PCT Published Patent Applications claiming priority to U.S. Serial Nos. 08/738,652 and 08/960,774, filed on October